October 13, 2025Open Access

Perioperative and Oncologic Outcomes of Secondary Cytoreductive Surgery: A Retrospective Analysis from a Cancer Care Centre of Southern India

Puntos clave

Secondary cytoreductive surgery yields favorable progression-free survival and post-recurrence survival in selected patients with platinum-sensitive relapsed epithelial ovarian cancer.
The mean post-recurrence survival was 38 months overall, with no significant difference between patients undergoing upfront and after systemic therapy.
Complications were manageable with 34% incidence, primarily grade 1–2, highlighting the procedure's safety profile.
Retrospective cohort study involving 47 patients at a tertiary cancer center aids in refining patient selection criteria for secondary surgery.

Resumen

Abstract Background Epithelial ovarian cancer (EOC) frequently relapses despite optimal primary treatment, with platinum-sensitive disease presenting a therapeutic challenge. Secondary cytoreductive surgery (SCS) may improve outcomes in select patients, but evidence from randomized trials is mixed. This study evaluates perioperative and oncologic outcomes of SCS in platinum-sensitive relapsed EOC, comparing upfront SCS (primary surgery PS) versus SCS after systemic therapy (AS). Methods In this retrospective cohort study at a tertiary cancer center in Southern India (April 2017–December 2024), 47 patients with platinum-sensitive relapsed EOC meeting AGO DESKTOP III criteria (prior complete cytoreduction, ECOG 0–2, no ascites) underwent SCS. Patients were stratified into PS (n = 30) and AS (n = 17) groups. Progression-free survival (PFS) was from SCS to recurrence/death or censoring (December 31, 2024). Post-recurrence survival (PRS) was from relapse to death/censoring. Survival was analyzed using Kaplan-Meier curves, log-rank tests, and Cox models. Complications were graded by Clavien-Dindo classification. Results Groups were comparable in age (mean 50.8 years), BMI (27 kg/m²), and histology (high-grade serous: 80%). Mean platinum-free interval was 33.4 months (38 PS vs. 28 AS). Complete cytoreduction was achieved in all; hyperthermic intraperitoneal chemotherapy was used in 36.2%. Complications occurred in 34% (mostly grade 1–2); one mortality (neutropenia). Mean PFS was 21.8 months (21.4 PS vs. 20.1 AS; HR 0.98, 95% CI 0.52–1.83; P = 0.95). Mean PRS was 38 months (32.7 PS vs. 44.7 AS; HR 1.73, 95% CI 0.87–3.44; P = 0.121). Conclusions SCS yields favorable PFS and PRS in selected platinum-sensitive relapsed EOC patients, with a nonsignificant trend toward better PRS after upfront systemic therapy. Perioperative morbidity is acceptable. Prospective studies are needed to confirm benefits and refine selection criteria.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo